Clinical Trial Update: Alipogene Tiparvovec for the Treatment of LPLD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial of alipogene tiparvovec for lipoprotein lipase deficiency was withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lipoprotein Lipase Deficiency

Drugs mentioned

• Glybera (alipogene tiparvovec)

Snippet

Sponsor: UniQure Biopharma B.V. | Conditions: LPL Deficiency | Phase 2 | Status: WITHDRAWN